Cervical cancer blood biomarkers could improve early detection

A new study examining whether cervical cancer can be detected through a non-invasive blood test has begun in Brisbane.

University of Queensland researchers are leading the CLARITY cervical cancer study at the Royal Brisbane and Women’s Hospital.

Chief investigator Professor Andreas Obermair from UQ’s Queensland Centre for Gynaecological Cancer Research said the study will investigate the potential of blood biomarkers in the screening, monitoring and management of cervical cancer.

“The project has the potential to improve early detection, treatment responses and post-treatment surveillance, as well as support more personalised treatment approaches for women with cervical cancer,’’ Professor Obermair said.

“Despite advances in prevention and treatment, including the success of the Gardasil vaccine, cervical cancer continues to impose significant physical, emotional, and financial burdens on women worldwide.

“There are about 1000 women diagnosed with this cancer in Australia every year.

“There remains a critical need for more effective, non-invasive tools to support early detection, monitor treatment response, and guide clinical decision-making.’’

Professor Obermair said he hoped about 100 women would take part in the study over 2 years.

“The CLARITY study represents an important step towards developing less invasive diagnostic and monitoring tools for cervical cancer,’’ he said.

“A reliable, non-invasive test would also serve as a more accessible and acceptable alternative to current cervical screening methods, particularly for women who face cultural, systemic, or personal barriers.

“This is especially important for under-screened populations, including Aboriginal and Torres Strait Islander women and culturally diverse communities.’’